Grifols Class A/€GRF
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Grifols Class A
Grifols SA, operating under the ticker GRF, is a biopharmaceutical company specialized in the production of plasma-derived medicines. Founded in 1940 and headquartered in Barcelona, Spain, Grifols is engaged in the diagnosis, prevention, and treatment of a variety of diseases, with a strong focus on immunology, hematology, and intensive care sectors. The company operates globally, leveraging advanced technologies and rigorous quality processes to provide essential medical products.
Ticker
€GRF
Sector
Primary listing
BME
Employees
23,833
Headquarters
Website
Grifols Class A Metrics
BasicAdvanced
€7.3B
26.64
€0.45
0.98
€0.12
1.01%
Price and volume
Market cap
€7.3B
Beta
0.98
52-week high
€13.80
52-week low
€7.32
Average daily volume
12K
Dividend rate
€0.12
Financial strength
Current ratio
2.636
Quick ratio
0.806
Long term debt to equity
119.998
Total debt to equity
126.869
Interest coverage (TTM)
2.56%
Profitability
EBITDA (TTM)
1,652.516
Gross margin (TTM)
39.64%
Net profit margin (TTM)
3.99%
Operating margin (TTM)
18.89%
Effective tax rate (TTM)
37.62%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
4.18%
Return on equity (TTM)
4.99%
Valuation
Price to earnings (TTM)
26.639
Price to revenue (TTM)
1.062
Price to book
1.41
Price to tangible book (TTM)
-1.65
Price to free cash flow (TTM)
11.365
Free cash flow yield (TTM)
8.80%
Free cash flow per share (TTM)
1.059
Dividend yield (TTM)
1.01%
Growth
Revenue change (TTM)
9.32%
Earnings per share change (TTM)
132.60%
3-year revenue growth (CAGR)
12.66%
10-year revenue growth (CAGR)
7.40%
3-year earnings per share growth (CAGR)
67.45%
10-year earnings per share growth (CAGR)
-4.84%
10-year dividend per share growth (CAGR)
-7.44%
What the Analysts think about Grifols Class A
Analyst ratings (Buy, Hold, Sell) for Grifols Class A stock.
Bulls say / Bears say
In Q1 2025, Grifols posted a net profit of €60 million, up 179% year-over-year, with revenue rising 7.4% to €1.79 billion and adjusted EBITDA up 14.2%, demonstrating strong operational performance. (Reuters)
For full-year 2024, Grifols achieved revenue of €7.21 billion, a 10.2% increase year-over-year. Adjusted EBITDA grew nearly 22% to €1.78 billion, and net profit tripled to €157 million, surpassing market expectations. (Reuters)
Grifols’ 2025 outlook forecasts revenue of €7.5–7.6 billion and free cash flow of €350–400 million, prompting a 13% jump in share price and reflecting strong investor confidence in its growth prospects. (Reuters)
Despite attempts to reduce leverage, Grifols’ net debt stood high at 5.6x EBITDA at the end of 2024, resulting in significant interest expense pressure and restricting its financial flexibility. (Reuters)
Grifols is still under legal and regulatory scrutiny, following Gotham City Research’s accusations of misleading accounting and active investigations by the CNMV and the High Court. This ongoing situation impacts its reputation and could lead to additional costs. (Reuters)
Rising trade tensions between the US and China threaten Grifols’ albumin business. China’s possible 125% tariffs on US-made albumin could impact its margins, while exemption status is not yet guaranteed. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Grifols Class A Financial Performance
Revenues and expenses
Grifols Class A Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols Class A stock?
Grifols Class A (GRF) has a market cap of €7.3B as of September 15, 2025.
What is the P/E ratio for Grifols Class A stock?
The price to earnings (P/E) ratio for Grifols Class A (GRF) stock is 26.64 as of September 15, 2025.
Does Grifols Class A stock pay dividends?
Yes, the Grifols Class A (GRF) stock pays dividends to shareholders. As of September 15, 2025, the dividend rate is €0.1215 and the yield is 1.01%. Grifols Class A has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Grifols Class A dividend payment date?
The next Grifols Class A (GRF) dividend payment date is unconfirmed.
What is the beta indicator for Grifols Class A?
Grifols Class A (GRF) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.